Last edition
News about "cytokine release syndrome (CRS)"
US FDA Accepts Roche's Lunsumio-Polivy Filing for Relapsed Large B-Cell Lymphoma
The US Food and Drug Administration (FDA) has accepted Roche’s supplemental Biologics License Application for the Lunsumio and Polivy combination in relapsed or refractory large B-cell lymphoma. The filing is supported by Phase 3 SUNMO study data showing a 59 percent reduction in the risk of disease progression or death.
Cytokine Release Syndrome (CRS) | 19/06/2026 | By News Bureau
Phanes Therapeutics Presents First Clinical Data for Spevatamig in Metastatic Pancreatic Cancer
Early data from the Twinpeak study presented at ASCO GI 2026 show encouraging safety and efficacy of spevatamig combined with chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma.
Cytokine Release Syndrome (CRS) | 12/01/2026 | By News Bureau | 238
Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market
AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).
Cytokine Release Syndrome (CRS) | 03/10/2025 | By Dineshwori | 484
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy